Ashley Smith | 03/21/2014
The latest report from the MHRA contains a sober reminder of the importance of adequate labelling of experimental drugs.
Last week, the MHRA published its GCP Inspections Reports covering the 161 inspections it carried out in the year to 31stMarch 2011.
Poor handling of data featured in several cases – especially confidential participant data being revealed. However, the most tragic error involved poor packaging and labelling of IMP (Investigational Medicinal Product) and the provisi...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
SmartLab Exchange USA 2025
08 - 09 April, 2025
Le Méridien, Fort Lauderdale, Florida, USA
Register Now |
View Agenda |
Learn More